{
  "ticker": "NYR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958508",
  "id": "02958508",
  "pages": 23,
  "price_sensitive": false,
  "date": "20250616",
  "time": "0830",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06krv9g3nqqv7k.pdf",
  "summary": "**Summary of ASX Announcement (Non-Deal Investor Presentation):**  \n\n- **Presentation Type:** Non-deal roadshow (no capital raising or transaction involved).  \n- **Key Highlights:**  \n  - **Lead Candidate (Xolatryp):** Phase I safety/tolerability trial ongoing (Cohort 4 completed; final results expected September 2025).  \n  - **Preclinical Efficacy:** Demonstrated in ischemic stroke (42% neuroprotection), traumatic brain injury (TBI), and myocardial infarction (86% cardioprotection).  \n  - **Catalysts:**  \n    - Phase I final results (Q3 2025); Phase II plan pending.  \n    - Cash balance: AU$4.76M (March 2025).  \n- **Market Opportunities:** Strokes (US$52B by 2032), TBI (US$5.5B), myocardial infarction (US$3.7B).  \n\n**No material trading/capital decisions identified.** Announcement focused on operational progress.",
  "usage": {
    "prompt_tokens": 4122,
    "completion_tokens": 212,
    "total_tokens": 4334,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T22:45:44.025419"
}